Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ibrutinib monotherapy in steroid-dependent or refractory chronic graft-versus-host disease (Japan)
jRCT2080223857Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Janssen Pharmaceutical. Started Apr 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCT2080223857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223857.